Published in Lancet on March 29, 2012
Diagnostic point-of-care tests in resource-limited settings. Lancet Infect Dis (2013) 3.56
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
Are randomized trials obsolete or more important than ever in the genomic era? Genome Med (2013) 1.33
Human genetics of tuberculosis: a long and winding road. Philos Trans R Soc Lond B Biol Sci (2014) 1.25
Pharmacogenetics in clinical practice: how far have we come and where are we going? Pharmacogenomics (2013) 1.15
Pharmacogenomics in clinical practice and drug development. Nat Biotechnol (2012) 1.08
Pharmacogenomics in the pocket of every patient? A prototype based on quick response codes. J Am Med Inform Assoc (2013) 1.07
Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. ISRN Pharmacol (2013) 0.98
Implementation and utilization of genetic testing in personalized medicine. Pharmgenomics Pers Med (2014) 0.97
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J (2013) 0.96
The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system. Genome Med (2013) 0.95
The CYP2C19*17 variant is not independently associated with clopidogrel response. J Thromb Haemost (2013) 0.94
The rise of multiple imputation: a review of the reporting and implementation of the method in medical research. BMC Med Res Methodol (2015) 0.94
High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. Cardiovasc Diagn Ther (2013) 0.91
Clinical pharmacogenomics: opportunities and challenges at point of care. Clin Pharmacol Ther (2012) 0.91
Pharmacogenomics: Current State-of-the-Art. Genes (Basel) (2014) 0.90
Genotype-based clinical trials in cardiovascular disease. Nat Rev Cardiol (2015) 0.89
Genetics of platelet inhibitor treatment. Br J Clin Pharmacol (2014) 0.89
Comparison of delivery strategies for pharmacogenetic testing services. Pharmacogenet Genomics (2014) 0.87
Pharmacogenetic testing: Current Evidence of Clinical Utility. Ther Adv Drug Saf (2013) 0.87
Genotype- and Phenotype-Directed Personalization of Antiplatelet Treatment in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing Coronary Stenting. Korean Circ J (2013) 0.84
Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? J Hum Genet (2013) 0.83
Genomics in cardiovascular disease. J Am Coll Cardiol (2013) 0.83
Personalized cardiovascular medicine: concepts and methodological considerations. Nat Rev Cardiol (2013) 0.82
Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials. Br J Clin Pharmacol (2015) 0.82
Pharmacogenomics of anti-platelet and anti-coagulation therapy. Curr Cardiol Rep (2013) 0.81
Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. Circ Res (2013) 0.81
Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. Circulation (2015) 0.81
Molecular oncology testing in resource-limited settings. J Mol Diagn (2014) 0.81
The genetics of drug efficacy: opportunities and challenges. Nat Rev Genet (2016) 0.81
Doubly blind: a systematic review of gender in randomised controlled trials. Glob Health Action (2016) 0.80
Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention. PLoS One (2014) 0.80
The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19. Expert Opin Drug Metab Toxicol (2015) 0.79
Using systems approaches to address challenges for clinical implementation of pharmacogenomics. Wiley Interdiscip Rev Syst Biol Med (2013) 0.79
Implementation of a clinical research pharmacogenomics program at an academic medical center: role of the genetics healthcare professional. Pharmacogenomics (2013) 0.79
Understanding the economic value of molecular diagnostic tests: case studies and lessons learned. J Pers Med (2013) 0.79
Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med (2015) 0.79
Personalised antiplatelet treatment: a RAPIDly moving target. Lancet (2012) 0.78
Feasibility of a microarray-based point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity. Biomed Res Int (2013) 0.78
Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. Eur J Clin Pharmacol (2015) 0.78
Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics? Can J Cardiol (2012) 0.77
A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Pharmacogenomics J (2015) 0.77
Pharmacogenetic guidance for antiplatelet treatment. Lancet (2012) 0.77
Pharmacogenetics: Point-of-care genetic testing--a new frontier explored. Nat Rev Cardiol (2012) 0.76
A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study. PLoS One (2014) 0.76
Pharmacogenetics in Jewish populations. Drug Metabol Drug Interact (2014) 0.75
Real-world efficiency of pharmacogenetic screening for carbamazepine-induced severe cutaneous adverse reactions. PLoS One (2014) 0.75
Cardiovascular genetics: technological advancements and applicability for dilated cardiomyopathy. Neth Heart J (2015) 0.75
Has the Human Genome Project Delivered for Healthcare? Ann Med Surg (Lond) (2012) 0.75
Exploring predisposition and treatment response--the promise of genomics. Prog Cardiovasc Dis (2012) 0.75
Clopidogrel resistance - a clear problem with an unclear solution. Indian Heart J (2012) 0.75
Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? Curr Opin Cardiol (2013) 0.75
Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients. Genet Test Mol Biomarkers (2016) 0.75
Pharmacogenetic guidance for antiplatelet treatment. Lancet (2012) 0.75
Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools. BMC Psychiatry (2017) 0.75
Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping. J Am Heart Assoc (2013) 0.75
The CYP2C19(∗)1/(∗)2 Genotype Does Not Adequately Predict Clopidogrel Response in Healthy Malaysian Volunteers. Cardiol Res Pract (2013) 0.75
Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention. Expert Rev Cardiovasc Ther (2017) 0.75
Bringing pharmacogenetics to the bedside. Eur J Clin Pharmacol (2012) 0.75
The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review. Eur J Clin Pharmacol (2015) 0.75
Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome. J Int Med Res (2016) 0.75
Personalizing antiplatelet therapy-moving to clinics. Eur J Clin Pharmacol (2012) 0.75
Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system. Pharm Pract (Granada) (2017) 0.75
A common allele on chromosome 9 associated with coronary heart disease. Science (2007) 20.37
Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol (2007) 13.46
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med (2010) 8.28
Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med (2007) 7.99
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med (2013) 6.40
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol (2009) 6.00
Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med (2015) 5.36
High risk clinical characteristics for subarachnoid haemorrhage in patients with acute headache: prospective cohort study. BMJ (2010) 4.65
The Canadian C-spine rule versus the NEXUS low-risk criteria in patients with trauma. N Engl J Med (2003) 4.48
Comparison of the Canadian CT Head Rule and the New Orleans Criteria in patients with minor head injury. JAMA (2005) 4.35
Clinical decision rules to rule out subarachnoid hemorrhage for acute headache. JAMA (2013) 4.34
Derivation of the San Francisco Syncope Rule to predict patients with short-term serious outcomes. Ann Emerg Med (2004) 4.12
Advanced cardiac life support in out-of-hospital cardiac arrest. N Engl J Med (2004) 4.09
Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol (2010) 4.08
CATCH: a clinical decision rule for the use of computed tomography in children with minor head injury. CMAJ (2010) 4.03
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev (2011) 3.44
A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2008) 3.44
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
The Canadian C-spine rule performs better than unstructured physician judgment. Ann Emerg Med (2003) 3.12
Rocuronium versus succinylcholine for rapid sequence induction intubation. Cochrane Database Syst Rev (2008) 3.08
Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol (2003) 3.07
Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol (2010) 3.07
BIPHASIC Trial: a randomized comparison of fixed lower versus escalating higher energy levels for defibrillation in out-of-hospital cardiac arrest. Circulation (2007) 2.80
Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA (2003) 2.74
Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol (2004) 2.70
Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J (2007) 2.63
Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev (2009) 2.61
Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation (2007) 2.59
Implementation of the Canadian C-Spine Rule: prospective 12 centre cluster randomised trial. BMJ (2009) 2.58
The OPALS Major Trauma Study: impact of advanced life-support on survival and morbidity. CMAJ (2008) 2.51
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. Circulation (2010) 2.51
Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol (2002) 2.47
Prospective validation of the ABCD2 score for patients in the emergency department with transient ischemic attack. CMAJ (2011) 2.45
Variation in management of recent-onset atrial fibrillation and flutter among academic hospital emergency departments. Ann Emerg Med (2010) 2.44
Optimal defibrillation response intervals for maximum out-of-hospital cardiac arrest survival rates. Ann Emerg Med (2003) 2.42
Do statins improve outcomes and reduce the incidence of vasospasm after aneurysmal subarachnoid hemorrhage: a meta-analysis. Stroke (2008) 2.23
Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands. Circulation (2011) 2.23
Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol (2009) 2.23
Prognostic value of 64-slice cardiac computed tomography severity of coronary artery disease, coronary atherosclerosis, and left ventricular ejection fraction. J Am Coll Cardiol (2010) 2.21
The out-of-hospital validation of the Canadian C-Spine Rule by paramedics. Ann Emerg Med (2009) 2.17
Diagnostic accuracy and impact of computed tomographic coronary angiography on utilization of invasive coronary angiography. Circ Cardiovasc Imaging (2009) 2.16
Retrospective application of the NEXUS low-risk criteria for cervical spine radiography in Canadian emergency departments. Ann Emerg Med (2004) 2.15
Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail (2012) 2.13
Repeatable noninvasive measurement of mouse myocardial glucose uptake with 18F-FDG: evaluation of tracer kinetics in a type 1 diabetes model. J Nucl Med (2013) 2.10
Prognostic value of CT angiography in coronary bypass patients. JACC Cardiovasc Imaging (2011) 2.10
Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry. Circ Cardiovasc Interv (2012) 2.07
Multicentre prospective validation of use of the Canadian C-Spine Rule by triage nurses in the emergency department. CMAJ (2010) 2.07
A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med (2003) 2.04
A prospective cohort study of patients with transient ischemic attack to identify high-risk clinical characteristics. Stroke (2013) 2.03
Accelerating risk of Fidelis lead fracture. Heart Rhythm (2008) 1.98
The impact of therapeutic hypothermia as adjunctive therapy in a regional primary PCI program. Resuscitation (2012) 1.97
Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol (2008) 1.96
Natural history and management of aortocoronary saphenous vein graft aneurysms: a systematic review of published cases. Circulation (2012) 1.93
Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol (2005) 1.90
Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol (2004) 1.90
Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain (2012) 1.88
Development of a clinical prediction rule for 30-day cardiac events in emergency department patients with chest pain and possible acute coronary syndrome. Ann Emerg Med (2011) 1.78
Understanding and improving low bystander CPR rates: a systematic review of the literature. CJEM (2008) 1.77
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ (2009) 1.76
Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm (2011) 1.73
Can differences in corrected coronary opacification measured with computed tomography predict resting coronary artery flow? J Am Coll Cardiol (2011) 1.70
Effect of transport interval on out-of-hospital cardiac arrest survival in the OPALS study: implications for triaging patients to specialized cardiac arrest centers. Ann Emerg Med (2009) 1.69
External validation of the San Francisco Syncope Rule in the Canadian setting. Ann Emerg Med (2009) 1.69
Transcutaneous electrical nerve stimulation (TENS) versus placebo for chronic low-back pain. Cochrane Database Syst Rev (2008) 1.69
Usefulness of mean platelet volume as a biomarker for long-term outcomes after percutaneous coronary intervention. Am J Cardiol (2010) 1.66
Kinesin family member 6 variant Trp719Arg does not associate with angiographically defined coronary artery disease in the Ottawa Heart Genomics Study. J Am Coll Cardiol (2009) 1.64
Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev (2013) 1.62
Should spectrophotometry be used to identify xanthochromia in the cerebrospinal fluid of alert patients suspected of having subarachnoid hemorrhage? Stroke (2006) 1.61
Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev (2014) 1.60
Clinically important change in the visual analog scale after adequate pain control. Acad Emerg Med (2003) 1.60
A KCNQ1 mutation causes a high penetrance for familial atrial fibrillation. J Cardiovasc Electrophysiol (2013) 1.60
A risk scoring system to identify emergency department patients with heart failure at high risk for serious adverse events. Acad Emerg Med (2013) 1.59
Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial. Ann Thorac Surg (2011) 1.56
Epinephrine infusion in the evaluation of unexplained cardiac arrest and familial sudden death: from the cardiac arrest survivors with preserved Ejection Fraction Registry. Circ Arrhythm Electrophysiol (2012) 1.56
Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions. Thromb Haemost (2012) 1.54